Key regions: France, India, United Kingdom, South Korea, Japan
The Multiple Sclerosis Drugs market in CIS has been experiencing steady growth over the past few years.
Customer preferences: Patients suffering from Multiple Sclerosis in CIS have been showing a preference towards disease-modifying therapies that help slow down the progression of the disease. This has led to an increase in demand for drugs that can modify the immune system and reduce inflammation in the central nervous system.
Trends in the market: One of the major trends in the CIS Multiple Sclerosis Drugs market is the increasing availability of biosimilars. Biosimilars are generic versions of biologic drugs that have the same efficacy and safety profile as the original drug. The availability of biosimilars has led to increased competition among drug manufacturers, resulting in lower prices for patients. Another trend in the market is the growing focus on patient-centric care. Pharmaceutical companies are investing in developing drugs that are more effective and have fewer side effects, thereby improving the quality of life of patients.
Local special circumstances: The CIS region comprises countries with different levels of economic development and healthcare infrastructure. This has resulted in varying levels of access to healthcare and medication for patients suffering from Multiple Sclerosis. While countries like Russia and Kazakhstan have well-developed healthcare systems, other countries like Tajikistan and Kyrgyzstan have limited access to healthcare and medication.
Underlying macroeconomic factors: The CIS region has been experiencing economic growth over the past few years, which has led to an increase in disposable income among the population. This has resulted in an increase in demand for healthcare services, including medication for chronic diseases like Multiple Sclerosis. Additionally, the region has a large population of working-age adults, who are more likely to be diagnosed with Multiple Sclerosis. This has led to an increase in the number of patients seeking treatment for the disease.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
